Live
- 10 Tried-and-Tested Home Remedies for Toothaches
- Thila Taila Abhishekah Pooja to Lord Shaneswara
- Sudheer Babu’s ‘Harom Hara’ set to release on this auspicious day
- Priyanka Gandhi says BJP talking of 'tinkering' with Constitution with PM’s nod
- Vishwak Sen unveils gritty avatar as ‘Lankala Rathna’ in ‘Gangs of Godavari’ teaser
- ‘Kalki 2898 AD’ locks release date; film to entertain audience from June last week
- LS polls: PM Modi says BJP-NDA leading 2-0 after first two phases
- Plea in Madras HC seeks special polling arrangement for names 'missing' from Coimbatore voter list
- Ex CM KCR Bus tour on 4 th day
- Youth National Games 2024 kick-start in Delhi; over 5,000 athletes from 15 states vying for top honours
Cipla top loser in Nifty as US FDA issues warning letter
Cipla shares were down by more than 7 per cent on Thursday after the US FDA issued a warning letter pertaining to its Pithampur manufacturing facility.
New Delhi: Cipla shares were down by more than 7 per cent on Thursday after the US FDA issued a warning letter pertaining to its Pithampur manufacturing facility.
Cipla shares were trading at Rs 1,172, down 7.8 per cent.
Cipla said it has received a warning letter dated November 17 from US Food and Drug Administration (FDA) for the routine current Good Manufacturing Practices (cGMP) inspection conducted at our Pithampur manufacturing facility between February 6-17, 2023.
“This Warning Letter summarises contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections,” Cipla said.
“The company will respond to the Warning Letter within the stipulated timelines and work closely with the FDA to address the concerns in a holistic and timely manner to ensure sustained compliance.
"We uphold quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards," it added.
